Title:

Reduced Incidence of Opioid-Induced Respiratory Depression with Oliceridine

Compared to Morphine As Measured By The Frequency And Average Cumulative

**Duration of Dosing Interruption In Patients Treated For Acute Postoperative Pain** 

Authors: Sabry Ayad, MD<sup>1,4</sup>; Mark A Demitrack, MD<sup>2</sup>; David A Burt PhD<sup>2</sup>; Cathy

Michalsky, MS<sup>2</sup>; Linda Wase, MD<sup>2</sup>; Michael J Fossler, PharmD, PhD<sup>2</sup>; Ashish

K.Khanna, MD,FCCP,FCCM<sup>3,4</sup>

Affiliation:

1. Cleveland Clinic, Outcomes Research, Anesthesiology Institute, Fairview

Hospital, Cleveland OH, USA

2. Trevena Inc., Chesterbrook, PA, USA

3. Wake Forest School of Medicine, Winston-Salem, NC, USA

4. Outcomes Research Consortium, Cleveland, OH

**Corresponding Author:** 

Dr Sabry Ayad,

Anesthesiology Institute, Outcomes Research, Fairview Hospital, Cleveland Clinic,

18101 Lorain Avenue, Cleveland, OH 44111, USA; Tel: +1 216 476 7052; E-mail:

Saayad@ccf.org

**Journal:** Clinical Drug Investigation

## Multicenter, randomized, double-blind, placebo-and active-controlled phase 3 studies

- Age ≥ 18 and ≤ 75 years at screening
- ≥ 40 kg in body weight or a body mass index (BMI) of ≤ 35 kg/m<sup>2</sup>
- Scheduled to undergo primary surgery with no additional collateral procedures

·	Hard Tissue	Soft Tissue	
	(Bunionectomy)	(Abdominoplasty)	
Sample size, N	389	401	
(randomized and treated)			
Treatment period	48 hours	24 hours	
Anesthesia	Regional	General	
	(popliteal sciatic nerve		
	block)		
Pain entry criteria	NRS* ≥ 4 within 9 hours	NRS* ≥ 5 within 4 hours	
	after discontinuation of	from end of surgery	
	regional anesthesia		

**Key exclusion criteria:** sleep apnea, evidence of hemodynamic instability or respiratory insufficiency, or surgical/anesthetic complications

\*NRS= numeric rating scale for pain score

Treatment	Clinician- administered Loading Dose	Patient-administered Demand Dose	Clinician- administered Supplemental Dose
Oliceridine 1.5 m		0.1 mg	0.75 mg q1h PRN
	1.5 mg	0.35 mg	
		0.5 mg	
Morphine	4 mg	1 mg	2 mg q1h PRN
Placebo	Volume-matched solution	Volume-matched solution	Volume-matched solution

Multimodal therapy was not permitted; Rescue pain medication (etodolac 200 mg PO q6h PRN) was permitted during the treatment period if study medication was inadequate

Certified nurse anesthetists blinded to treatment monitored each patient and may have withheld study medication according to patient's respiratory status